Literature DB >> 27821671

Cost effectiveness of case-finding strategies for primary prevention of cardiovascular disease: a modelling study.

Catriona Crossan1, Joanne Lord2, Ronan Ryan3, Leo Nherera4, Tom Marshall5.   

Abstract

BACKGROUND: Policies of active case finding for cardiovascular disease (CVD) prevention in healthy adults are common, but economic evaluation has not investigated targeting such strategies at those who are most likely to benefit. AIM: To assess the cost effectiveness of targeted case finding for CVD prevention. DESIGN AND
SETTING: Cost-effectiveness modelling in an English primary care population.
METHOD: A cohort of 10 000 individuals aged 30-74 years and without existing CVD or diabetes was sampled from The Health Improvement Network database, a large primary care database. A discrete-event simulation was used to model the process of inviting people for assessment, assessing cardiovascular risk, and initiation and persistence with drug treatment. Risk factors and drug cessation rates were obtained from primary care data. Published sources provided estimates of uptake of assessment, treatment initiation, and treatment effects. The researchers determined the lifetime costs and quality-adjusted life years (QALYs) with opportunistic case finding, and strategies prioritising and targeting patients by age or prior estimate of cardiovascular risk. This study reports on the optimum strategy if a QALY is valued at £20 000.
RESULTS: Compared with no case finding, inviting all adults aged 30-74 years in a population of 10 000 yields 30.32 QALYs at a total cost of £705 732. The optimum strategy is to rank patients by prior risk estimate and invite 8% of those who are assessed as being at highest risk (those at ≥12.76% predicted 10-year CVD risk), yielding 17.53 QALYs at a cost of £162 280. There is an 89.4% probability that the optimum strategy is to invite <35% of patients for assessment.
CONCLUSION: Across all age ranges, targeted case finding using a prior estimate of CVD risk is more efficient than universal case finding in healthy adults. © British Journal of General Practice 2017.

Entities:  

Keywords:  cardiovascular diseases; cost-effectiveness; primary care; risk stratification; screening

Mesh:

Year:  2016        PMID: 27821671      PMCID: PMC5198616          DOI: 10.3399/bjgp16X687973

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  34 in total

1.  Estimating uncertainty ranges for costs by the bootstrap procedure combined with probabilistic sensitivity analysis.

Authors:  J Lord; M A Asante
Journal:  Health Econ       Date:  1999-06       Impact factor: 3.046

2.  Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study.

Authors:  Tom Marshall; Andrew Rouse
Journal:  BMJ       Date:  2002-07-27

3.  Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.

Authors:  J Robson
Journal:  Heart       Date:  2008-08-13       Impact factor: 5.994

4.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

Authors:  Sarah Lewington; Robert Clarke; Nawab Qizilbash; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321

Review 5.  Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy.

Authors:  M Law; N Wald; J Morris
Journal:  Health Technol Assess       Date:  2003       Impact factor: 4.014

6.  Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.

Authors:  M R Law; N J Wald; J K Morris; R E Jordan
Journal:  BMJ       Date:  2003-06-28

Review 7.  First-line drugs for hypertension.

Authors:  James M Wright; Vijaya M Musini
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

8.  The Sandwell Project: a controlled evaluation of a programme of targeted screening for prevention of cardiovascular disease in primary care.

Authors:  Tom Marshall; Paul Westerby; Jenny Chen; Mary Fairfield; Jenny Harding; Ruth Westerby; Rajai Ahmad; John Middleton
Journal:  BMC Public Health       Date:  2008-02-25       Impact factor: 3.295

9.  Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore.

Authors:  Julia Hippisley-Cox; Carol Coupland; John Robson; Aziz Sheikh; Peter Brindle
Journal:  BMJ       Date:  2009-03-17

Review 10.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.

Authors:  M R Law; J K Morris; N J Wald
Journal:  BMJ       Date:  2009-05-19
View more
  14 in total

Review 1.  Case-finding for common mental disorders in primary care using routinely collected data: a systematic review.

Authors:  Harriet Larvin; Emily Peckham; Stephanie L Prady
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-07-12       Impact factor: 4.328

2.  Delivery and impact of the NHS Health Check in the first 8 years: a systematic review.

Authors:  Adam Martin; Catherine L Saunders; Emma Harte; Simon J Griffin; Calum MacLure; Jonathan Mant; Catherine Meads; Fiona M Walter; Juliet A Usher-Smith
Journal:  Br J Gen Pract       Date:  2018-06-18       Impact factor: 5.386

3.  Modelling tool to support decision-making in the NHS Health Check programme: workshops, systematic review and co-production with users.

Authors:  Martin O'Flaherty; Ffion Lloyd-Williams; Simon Capewell; Angela Boland; Michelle Maden; Brendan Collins; Piotr Bandosz; Lirije Hyseni; Chris Kypridemos
Journal:  Health Technol Assess       Date:  2021-05       Impact factor: 4.014

4.  NHS Health Checks: an observational study of equity and outcomes 2009-2017.

Authors:  John Robson; Cesar Garriga; Carol Coupland; Julia Hippisley-Cox
Journal:  Br J Gen Pract       Date:  2021-08-26       Impact factor: 6.302

5.  Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study.

Authors:  Julia Hippisley-Cox; Carol Coupland; Peter Brindle
Journal:  BMJ       Date:  2017-05-23

6.  The current and potential health benefits of the National Health Service Health Check cardiovascular disease prevention programme in England: A microsimulation study.

Authors:  Oliver T Mytton; Christopher Jackson; Arno Steinacher; Anna Goodman; Claudia Langenberg; Simon Griffin; Nick Wareham; James Woodcock
Journal:  PLoS Med       Date:  2018-03-06       Impact factor: 11.069

7.  Future cost-effectiveness and equity of the NHS Health Check cardiovascular disease prevention programme: Microsimulation modelling using data from Liverpool, UK.

Authors:  Chris Kypridemos; Brendan Collins; Philip McHale; Helen Bromley; Paula Parvulescu; Simon Capewell; Martin O'Flaherty
Journal:  PLoS Med       Date:  2018-05-29       Impact factor: 11.069

8.  Comparing Strategies for Modeling Competing Risks in Discrete-Event Simulations: A Simulation Study and Illustration in Colorectal Cancer.

Authors:  Koen Degeling; Hendrik Koffijberg; Mira D Franken; Miriam Koopman; Maarten J IJzerman
Journal:  Med Decis Making       Date:  2019-01       Impact factor: 2.583

9.  What should selective cardiometabolic prevention programmes in European primary care look like? A consensus-based design by the SPIMEU group.

Authors:  Norbert Král; Anne-Karien M de Waard; François G Schellevis; Joke C Korevaar; Christos Lionis; Axel C Carlsson; Anders Larrabee Sønderlund; Jens Søndergaard; Lars Bruun Larsen; Monika Hollander; Trine Thilsing; Agapi Angelaki; Niek J de Wit; Bohumil Seifert
Journal:  Eur J Gen Pract       Date:  2019-08-14       Impact factor: 1.904

10.  NHS health checks: a cross- sectional observational study on equity of uptake and outcomes.

Authors:  N Coghill; L Garside; A A Montgomery; G Feder; J Horwood
Journal:  BMC Health Serv Res       Date:  2018-04-03       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.